Espère Healthcare Ltd

Working with research based partners in Europe and North America, Espère Healthcare Ltd has pioneered the development of a range of innovative solutions for the treatment of various skin and wound care related conditions.

Our products can be accessed via a number of specific websites which provide you with all the information necessary to make an informed choice regarding their use. We believe that it is important that prescribers, parents and patients have access to products that have been trialled, tested and found to be effective, so all our products start life in clinical settings.


Operating Address

11D Old Bridge Way, Shefford, SG17 5HQ

Tel: 01462 346100

Email: sales@esperehealth.co.uk

Registered Address

Shefford House, 15 High Street, Shefford, SG17 5DD

Company Registration Number: 05032968

VAT Registration Number: GB829924290

Espère Healthcare is all about transforming lives with trusted medical devices. Discover our range of products, trusted by customers worldwide for over 20 years.

Espère Healthcare Ltd has been dedicated to improving lives through our products, people, attitude, service, and activities.

We specialise in registered medical devices that effectively treat persistent skin conditions, even when other medical interventions have not worked. Our products are carefully chosen from both small and global manufacturers, ensuring they perform exactly as described. Our company has grown thanks to the quality of our people and the reliability of our service. We have earned a reputation for providing evidence-based, impartial advice and prompt delivery. We serve a wide range of clients, from the NHS to families dealing with conditions like eczema.

Recently, we became part of the BAP Medical group of companies. After two decades, we are now treating the second generation of patients and supporting their caregivers. We look forward to continuing our mission for the next 20 years and beyond.


You can find our products on several specific websites that provide all the information you need to make an informed decision. We believe it’s important for prescribers, parents, and patients to have access to products that have been thoroughly tested and proven effective. That's why all our products are first used in clinical settings before becoming available to you.


OPERATING ADDRESS

11D Old Bridge Way, Shefford, SG17 5HQ

Tel: 01462 346100

Email: sales@esperehealth.co.uk

Certificate No. 367342021

REGISTERED ADDRESS

Shefford House, 15 High Street, Shefford, SG17 5DD

Company Registration Number: 05032968

VAT Registration Number: GB829924290


Slavery and human trafficking statement 2024

Introduction

We are committed to eliminating acts of modern-day slavery and human trafficking within our business and from within our supply chains. Our annual turnover is under £36 million and although we are not legally obliged to report on slavery and human trafficking, this statement is made in accordance with section 54(1) of the Modern Slavery Act 2015 and is our slavery and human trafficking statement for the financial year ending 31st December 2023.

Organisational structure, business and supply chains

We are a supplier of Registered Medical Devices to the Public and Private Healthcare Sectors and are an independent company operating solely within the UK. Our business comprises one Head Office and warehouse unit based at the above address. Our supply chains are all EU based suppliers of Wound dressings, creams, liquids, clothing and bedding. Most of our materials or supplies are sourced directly from manufacturers.

Policy on slavery and human trafficking

We are committed to ensuring that there is no modern slavery or human trafficking in any part of our business or in our supply chains. This policy reflects our commitment to acting ethically and with integrity in all our business relationships and to implementing and enforcing effective systems and controls to ensure slavery and human trafficking is not taking place anywhere within our supply chains.

Due diligence

We consider ourselves to be a ‘low risk’ business with regard to slavery and human trafficking. However, we foster a culture that encourages the identification and reporting of any such risks within our business. We recruit all our employees either directly or through recruitment agencies who are members of the Recruitment and Employment Confederation. We do not recruit from outside the UK or use agency workers.

Assessing and managing risk

We have a whistleblowing policy in place and, as part of our efforts to identify and mitigate risks within our supply chain, we are introducing systems to identify, assess and monitor potential risk areas.

Effectiveness in combating slavery and human trafficking

We have zero tolerance to slavery and human trafficking. To ensure that all those in our supply chains comply with our values we are putting in place a supply chain compliance programme that will require our suppliers to confirm that they have a slavery and human trafficking policy in place and that they require the same from their suppliers.

Training

We are providing appropriate training to ensure that relevant employees understand the risks of modern slavery and human trafficking within our business and supply chains.

 

The above statement was approved and signed by the Managing Director of Espère Healthcare Ltd in March 2024.
 
Chris Steeples

Managing Director

1st March 2024

Carbon Reduction Plan - Espère Healthcare Ltd

Publication date: April 2024

Commitment to achieving Net Zero

Espere Healthcare Ltd is committed to achieving Net Zero emissions by 2050.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year 2023

Additional Details relating to the Baseline Emissions calculations.

This is the first full year of emissions reporting following the expansion of the business’ Commercial unit and subsequent market expansion.

Emissions TOTAL (tCO2e)
Scope 1 0.2
Scope 2 1.1

Scope 3

(Included Sources)

14.1 of which

  • 4.3 - Commuting
  • 6.8 - In-work Travel
  • 0.8 - Plane Travel
  • 0.9 - Hotel Emissions
Total Emissions 15.41 – equivalent to 1.71 per employee

 

Current Emissions Reporting Not yet available

Emissions TOTAL (tCO2e)
Scope 1 xx
Scope 2 xx
Scope 3 xx
Total Emissons xx

 

Emissions reduction targets

With a growing, evolving small business it is difficult to commit to an overall reduction in emissions as additional staff which may be employed in the next 3-5 years will have the effect of increasing the overall company emissions in the short term. In order to make sense of our progress to achieving Net Zero, we have adopted the following carbon reduction targets, based upon a CO2 figure per employee.

We project that carbon emissions will decrease over the next five years from the current 1.71 tonnes per employee to 1.2 tCO2e per employee by 2030. This is a reduction of 30%.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following environmental management measures and projects have been completed or implemented since before the 2023 baseline so they are outside the scope of the plan but reflect the desire of the company to do all it can to progress the road to carbon neutrality.

  • Centralising the packaging and despatch facility allowed for a general reduction in business travel to support warehouse activities.

  • We have already replaced all of our lighting in the office and warehouse to LED

  • We have recently transferred to a green energy supplier for gas and electricity

  • All computer screens are low emission panels

  • Our Sales team run Hybrid vehicles and replace car travel with train and tube wherever possible in inner cities

  • 40% of meetings are now conducted remotely, reducing travel costs

  • Open windows have replaced air conditioning in the Summer Months

  • All received packaging is recycled in our despatch department.

The carbon emission reduction achieved by these schemes equate to approximately 3 tCO2e, prior to the calculation of the 2023 baseline. There is obviously an ongoing benefit and the measures will be in effect when performing the contract. 

 

In the future we hope to implement further measures such as:

  • Full electrification of the Sales vehicles. (The MD has already transitioned from Diesel to pure Electric, but range hampers the progression of the sales team from hybrids)
  • Investigating the transition of electricity to solar and / or night charging battery technology. (Scope 2 is only 7% of our CO2 usage so gains will be minimal)
  •  Adding a controllable “Hive” type system to the heating to make the building more economical in the winter months. Again, a heat pump heating solution would be considered when the current domestic, sized boiler nears end of life but Scope 1 costs are only 0.2 tCO2e so there is little to gain in terms of carbon reduction as the boiler tends to only be used for 3-4 months of the year. 

 

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard1 and uses the appropriate Government emission conversion factors for greenhouse gas company reporting2.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard3.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors.

The above statement was approved and signed on behalf of the supplier by the Managing Director of Espère Healthcare Ltd.

Chris Steeples

Managing Director

8th April 2024